Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine

Phase 4

Completed

Conditions: Migraine

Interventions: Biological: Erenumab
Drug: Topiramate
Drug: Topiramate matching placebo
Biological: Erenumab matching placebo

First Posted Date: 2019-02-04

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 777

Registration Number: NCT03828539

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Phase 2

Active, not recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: LYS006
Drug: Placebo to LYS006
Drug: Placebo to MAS825
Drug: Placebo to CFZ533
Drug: LOU064 25mg
Drug: CFZ533
Drug: LOU064 100mg
Drug: Placebo to VAY736
Drug: VAY736
Drug: Placebo to LOU064
Drug: MAS825

First Posted Date: 2019-02-01

Last Posted Date: 2025-01-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 248

Registration Number: NCT03827798

Locations: 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸
Olympian Clinical Research ., Clearwater, Florida, United States
🇺🇸
Park Avenue Dermatology, PA, Orange Park, Florida, United States

and more 6 locations

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib
Drug: Anastrozole
Drug: Letrozole
Drug: Goserelin

First Posted Date: 2019-01-30

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 376

Registration Number: NCT03822468

Locations: 🇺🇸
Southern Cancer Center PC, Mobile, Alabama, United States
🇺🇸
Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸
Nebraska Cancer Specialists, Omaha, Nebraska, United States

and more 12 locations

Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients

Phase 3

Active, not recruiting

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: Crizanlizumab (SEG101)
Drug: Placebo

First Posted Date: 2019-01-24

Last Posted Date: 2024-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 258

Registration Number: NCT03814746

Locations: 🇺🇸
Childrens Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Levine Cancer Insitute Carolinas Healthcare System, Charlotte, North Carolina, United States

and more 3 locations

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Phase 3

Completed

Conditions: Heterozygous Familial Hypercholesterolemia
ASCVD
Elevated Cholesterol
Homozygous Familial Hypercholesterolemia

Interventions: Drug: Inclisiran Sodium

First Posted Date: 2019-01-23

Last Posted Date: 2024-03-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3275

Registration Number: NCT03814187

Locations: 🇺🇸
Research Site 10001-014, Columbus, Ohio, United States
🇺🇸
Research Site 10001-088, Houston, Texas, United States
🇺🇸
Research Site 10001-091, Houston, Texas, United States

and more 235 locations

A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia

Phase 2

Terminated

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: QAW039
Drug: Placebo

First Posted Date: 2019-01-18

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 9

Registration Number: NCT03810183

Locations: 🇬🇧
Novartis Investigative Site, Bradford, West Yorkshire, United Kingdom

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Phase 3

Terminated

Conditions: Central Retinal Vein Occlusion

Interventions: Drug: Aflibercept 2 mg
Drug: Brolucizumab 6 mg
Other: Sham injection

First Posted Date: 2019-01-18

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 493

Registration Number: NCT03810313

Locations: 🇬🇧
Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom

A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

Phase 2

Completed

Conditions: Presbyopia

Interventions: Drug: Placebo
Drug: UNR844-Cl

First Posted Date: 2019-01-18

Last Posted Date: 2022-05-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 125

Registration Number: NCT03809611

Locations: 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

Phase 2

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: Nidufexor
Other: Placebo
Drug: Standard of Care (SoC)

First Posted Date: 2019-01-15

Last Posted Date: 2022-08-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 83

Registration Number: NCT03804879

Locations: 🇹🇷
Novartis Investigative Site, Talas / Kayseri, Turkey

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion

Phase 3

Terminated

Conditions: Branch Retinal Vein Occlusion

Interventions: Drug: Brolucizumab 6 mg
Drug: Aflibercept 2 mg
Other: Sham injection

First Posted Date: 2019-01-14

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 450

Registration Number: NCT03802630

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy